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Disclaimer: This guideline is designed primarily as an educational resource for health care providers to help
them provide quality medical genetic services. Adherence to this guideline does not necessarily assure a
successful medical outcome. This guideline should not be considered inclusive of all proper procedures and
tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In
determining the propriety of any speciﬁc procedure or test, the geneticist should apply his or her own
professional judgment to the speciﬁc clinical circumstances presented by the individual patient or specimen. It
may be prudent, however, to document in the patient’s record the rationale for any signiﬁcant deviation from
this guideline.
Abstract: Isolated hemihyperplasia, formerly termed isolated hemihy-
pertrophy, is a congenital overgrowth disorder associated with an in-
creased risk for embryonal tumors, mainly Wilms tumor and hepato-
blastoma. This practice guideline will set forth the diagnostic criteria
and tumor screening recommendations for children with isolated hemi-
hyperplasia, based on the best information available. There is clinical
overlap between isolated hemihyperplasia with Beckwith-Wiedemann
syndrome. The majority of Beckwith-Wiedemann syndrome patients
have a molecular abnormality involving the imprinted cluster of genes
at 11p15.5. In contrast, the preponderance of isolated hemihyperplasia
patients studied have no identiﬁed etiology. Tumors have developed in
isolated hemihyperplasia patients with and without molecular abnor-
malities. For this reason, molecular diagnostics are not helpful in
identifying the subset of isolated hemihyperplasia patients with tumor
risk and all isolated hemihyperplasia patients should undergo tumor
screening. Genet Med 2009:11(3):220–222.
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DIAGNOSTIC CRITERIA FOR ISOLATED
HEMIHYPERPLASIA
Isolated hemihyperplasia (IH, OMIM 23500) is most suc-
cinctly deﬁned as asymmetric regional body overgrowth be-
cause of an underlying abnormality of cell proliferation in
individuals without any other underlying diagnosis. There are
no widely accepted criteria for deﬁning IH as distinct from
normal growth variation in children, and therefore the pragmatic
case deﬁnition is that IH should be apparent “from the end of
the bed.” The asymmetry can be due to differences in the
growth of bone, soft tissue, or both.
The diagnosis of IH should be made by a clinical geneticist
experienced in the differentiation of IH from other causes of
body asymmetry, including regional body undergrowth, seen
for example with mild ﬁbular hemimelia and hemiatrophy.
Known overgrowth syndromes, including Beckwith-Wiede-
mann syndrome (BWS), proteus syndrome, neuroﬁbromatosis
Type 1, mosaic trisomy 8, and disorders associated with vas-
cular malformations including Klippel-Trenaunay syndrome
and megalencephaly-cutis marmorata telangiectatica congeni-
tal, must be ruled out.
TUMOR OCCURRENCE IN
INDIVIDUALS WITH IH
The increased risk of embryonal tumors in individuals with
IH is well documented in case reports and clearly substantiated
by the only prospective study, which was reported by Hoyme et
al.1 in 1998. They followed 168 children with IH for 10 years
and reported 10 tumors in 9 individuals. There were six Wilms
tumors (WTs), one hepatoblastoma (HBL), two adrenal cell
carcinomas, and one small bowel leiomyosarcoma, giving a
tumor incidence of 5.9%. In a review of 134 tumors in IH
patients, Lapunzina2 noted that the types of tumors in IH pa-
tients are similar but not identical to those seen in BWS. As in
BWS, the IH tumors were mostly embryonal, 94% occurred in
the abdomen, and usually diagnosed before 10 years of age. The
six extraabdominal tumors involved the brain, testes, lung,
uterine cavity, and bone marrow.
ASSOCIATION BETWEEN OCCURRENCE AND
TYPES OF TUMORS WITH EPIGENETIC
CAUSES OF IH
Recognition that IH and BWS have clinical overlap and
similar tumor associations has led to the search for the same
constitutional epigenotypes involving the gene cluster at
11p15.5 in IH patients, that are known to underlie BWS. As of
early 2008, a minority of IH patients have indeed been found to
have one of the three most common epigenotypes found in
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loss of maternal methylation of KCNQ1OT1, and hypermethyl-
ation of maternal H19.3–8
Shuman et al.8, in 2006, reported the largest single cohort of
IH patients (51) studied for these molecular defects. They found
that 40 (78%) had no identiﬁed abnormality but had six tumors,
i.e., a tumor incidence of 15%. Eight (16%) patients had UPD
of whom four developed tumors for a tumor incidence of 50%.
Three (6%) had loss of maternal methylation of KCNQ1OT1
and none had tumors. No patients had hypermethylation of
maternal H19 alone. The authors point out that because UPD is
always mosaic, it can be missed and therefore it is likely that a
subset of patients without identiﬁed molecular defects may
actually have UPD. The authors also noted that of the four UPD
patients with tumors, two were conceived by assisted reproduc-
tive technologies, raising the question of whether assisted re-
productive technology is a risk factor for IH because of UPD
and associated high tumor risk.
Niemitz et al.9, in 2005, reported the results of similar mo-
lecular studies on 15 IH children with WT, and noted that 12/15
(80%) had no identiﬁed abnormality, and all three of those with
abnormalities had hypermethylation of maternal H19, two be-
cause of UPD and one an isolated methylation defect only.
These authors suggested that the methylation defect of H19 per
se, with or without UPD, confers a high tumor risk.
Overall, the preponderance of IH patients with or without
tumors who have undergone epigenetic studies have no identi-
ﬁed etiology. This is in contrast to BWS, 70% of whom have an
identiﬁed epigenetic or genetic etiology. Tumors have devel-
oped in IH patients with and without molecular abnormalities.
Therefore, current molecular techniques are not helpful in iden-
tifying the subset of IH patients with tumor risk and so all IH
patients should be screened for tumors. Similarly, data on tumor
risk for speciﬁc molecular defects is too limited to be clinically
useful at this time, although the studies noted above have
reported high tumor risk with methylation of H19 with or
without UPD.
EVIDENCE FOR EFFECTIVENESS OF EXISTING
TUMOR SURVEILLANCE PROTOCOLS
The purpose of tumor surveillance in high-risk individuals is
to facilitate identiﬁcation of tumors at an early stage when
treatment is most effective and least invasive. The most frequent
tumors in children with IH are WT and HBL, but other tumors
including neuroblastoma, adrenocortical tumors, and sarcomas
occur. The vast majority of tumors occur in the abdomen and,
given the ready availability and noninvasiveness of diagnostic
ultrasound, abdominal ultrasound is the screening modality of
choice for most tumors.
Beckwith in 1998 recommended abdominal ultrasound every
3 months until age 7 or 8 years for children with BWS. These
are the ages that 90% and 93%, respectively, of WT are diag-
nosed.10 He based his recommendation on the epidemiology and
biology of WT (including rapid WT growth), beneﬁts, risks, and
cost of monitoring for WT in BWS patients. Data on the
effectiveness of this protocol are somewhat limited for IH, as
studies have been retrospective and most studied patients have
had BWS. One such study is that by Choyke et al.11, who looked
at whether screened patients with BWS or IH who developed
WT had less late-stage disease than those not screened. Their
results suggested strongly that ultrasound screening at intervals
of 4 months or less reduced the proportion of late-stage WT.
Beckwith’s original protocol has also been recommended by
Tan et al.12, in 2006, after a comprehensive review of the
literature. All of the above authors have recognized the potential
adverse effects of ultrasound screening, primarily false positive
ﬁndings, some of which have led to invasive surgeries.11
Tan et al. have also recommended that serum alpha-fetopro-
tein (AFP) be measured every 3 months until age 4, by which
time 90% of HBL will have developed. They cite a case report
with this recommendation by Clericuzio et al.13, of ﬁve children
(three with BWS and two with IH) with normal hepatic ultra-
sounds for whom rising serial AFP measurements prompted
additional imaging and ultimate diagnosis of early stage HBL.
Caution in interpretation of infant AFP levels is necessary,
given the high levels of AFP at birth which fall rapidly to the
normal adult level by 10–12 months of age.14,15
Lastly, one of the authors (C.L.C.) is an advocate of teaching
parents the “daily caretaker abdominal examination” for young
children with IH.16 On the basis of this author’s personal expe-
rience, most parents are eager to take an active role in their
child’s care. Those that are too anxious to do the exam are fully
supported in not doing so. The beneﬁts of this practice are
anecdotal: one parent found a WT half-way through the 3 month
screening interval (personal observation). As there is no evi-
dence of an adverse effect of teaching parents the abdominal
examination, it seems reasonable to offer this education as an
option.
Recommendations
1. Any child with suspected IH should be referred to a
clinical geneticist for evaluation.
2. Abdominal ultrasound every 3 months until 7 years.
3. Serum alpha-fetoprotein measurement every 3 months
until 4 years.
4. Daily caretaker abdominal examination at the discretion
of the provider/parent.
REFERENCES
1. Hoyme HE, Seaver LH, Jones KL, Procopio F, Crooks W, Feingold M.
Isolated hemihyperplasia (hemihypertrophy): report of a prospective multi-
center study of the incidence of neoplasia and review. Am J Med Genet
1998;79:274–278.
2. Lapunzina P. Risk of tumorigenesis in overgrowth syndromes: a compre-
hensive review. Am J Med Genet C Semin Med Genet 2005;137:53–71.
3. Grundy P, Telzerow P, Paterson MC, et al. Chromosome 11 uniparental isodi-
somy predisposing to embryonal neoplasms. Lancet 1991;338:1079–1080.
4. Hertel NT, Carlsen N, Kerndrup G, et al. Late relapse of adrenocortical
carcinoma in Beckwith-Wiedemann syndrome. Clinical, endocrinological
and genetic aspects. Acta Paediatr 2003;92:439–443.
5. West PM, Love DR, Stapleton PM, Winship IM. Paternal uniparental
disomy in monozygotic twins discordant for hemihypertrophy. J Med Genet
2003;40:223–226.
6. Martin RA, Grange DK, Zehnbauer B, Debaun MR. LIT1 and H19 meth-
ylation defects in isolated hemihyperplasia. Am J Med Genet A 2005;134:
129–131.
7. Cooper WN, Luharia A, Evans GA, et al. Molecular subtypes and pheno-
typic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet
2005;13:1025–1032.
8. Shuman C, Smith AC, Steele L, et al. Constitutional UPD for chromosome
11p15 in individuals with isolated hemihyperplasia is associated with high
tumor risk and occurs following assisted reproductive technologies. Am J
Med Genet A 2006;140:1497–1503.
9. Niemitz EL, Feinberg AP, Brandenburg SA, Grundy PE, DeBaun MR.
Children with idiopathic hemihypertrophy and beckwith-wiedemann syn-
drome have different constitutional epigenotypes associated with wilms
tumor. Am J Hum Genet 2005;77:887–891.
10. Nichols KE, Li FP, Haber DA, Diller L. Childhood cancer predisposition:
applications of molecular testing and future implications. J Pediatr 1998;
132:389–397.
11. Choyke PL, Siegel MJ, Craft AW, Green DM, DeBaun MR. Screening for
Wilms tumor in children with Beckwith-Wiedemann syndrome or idiopathic
hemihypertrophy. Med Pediatr Oncol 1999;32:196–200.
12. Tan TY, Amor DJ. Tumour surveillance in Beckwith-Wiedemann syn-
Genetics IN Medicine • Volume 11, Number 3, March 2009 Tumor screening for hemihyperplasia
Genetics IN Medicine • Volume 11, Number 3, March 2009 221drome and hemihyperplasia: a critical review of the evidence and sug-
gested guidelines for local practice. J Paediatr Child Health 2006;42:
486–490.
13. Clericuzio CL, Chen E, McNeil DE, et al. Serum alpha-fetoprotein screening
for hepatoblastoma in children with Beckwith-Wiedemann syndrome or
isolated hemihyperplasia. J Pediatr 2003;143:270–272.
14. Tsuchida Y, Endo Y, Saito S, Kaneko M, Shiraki K, Ohmi K. Evaluation of
alpha-fetoprotein in early infancy. J Pediatr Surg 1978;13:155–162.
15. Ohama K, Nagase H, Ogino K, et al. Alpha-fetoprotein (AFP) levels in
normal children. Eur J Pediatr Surg 1997;7:267–269.
16. Clericuzio CL. Recognition and management of childhood cancer syn-
dromes: a systems approach. Am J Med Genet 1999;89:81–90.
Clericuzio and Martin Genetics IN Medicine • Volume 11, Number 3, March 2009
222 © 2009 Lippincott Williams & Wilkins